Business Description
H. Lundbeck AS
ISIN : DK0061804770
Share Class Description:
WBO:LUNB: Ordinary Shares - Class BCompare
Compare
Traded in other countries / regions
HLUN B.Denmark0ND5.UKLDBA.GermanyHLBBF.USALUNA.Austria IPO Date
2022-07-29Description
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.23 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 1.35 | |||||
| Interest Coverage | 51.43 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.14 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.1 | |||||
| 3-Year EBITDA Growth Rate | -40.8 | |||||
| 3-Year EPS without NRI Growth Rate | -31.6 | |||||
| 3-Year FCF Growth Rate | -40.2 | |||||
| 3-Year Book Growth Rate | -36.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -1.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.94 | |||||
| 9-Day RSI | 65.8 | |||||
| 14-Day RSI | 65.58 | |||||
| 6-1 Month Momentum % | 3.74 | |||||
| 12-1 Month Momentum % | -7.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.75 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 0.65 | |||||
| Days Inventory | 355.38 | |||||
| Days Sales Outstanding | 70.66 | |||||
| Days Payable | 336.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.85 | |||||
| Dividend Payout Ratio | 0.29 | |||||
| Forward Dividend Yield % | 1.85 | |||||
| 5-Year Yield-on-Cost % | 1.91 | |||||
| 3-Year Average Share Buyback Ratio | -70.9 | |||||
| Shareholder Yield % | 6.42 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.91 | |||||
| Operating Margin % | 16.08 | |||||
| Net Margin % | 11.99 | |||||
| FCF Margin % | 20.56 | |||||
| ROE % | 11.05 | |||||
| ROA % | 6.47 | |||||
| ROIC % | 9.36 | |||||
| ROC (Joel Greenblatt) % | 88.44 | |||||
| ROCE % | 10.46 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.49 | |||||
| Forward PE Ratio | 13.74 | |||||
| PE Ratio without NRI | 13.49 | |||||
| Shiller PE Ratio | 7.79 | |||||
| Price-to-Owner-Earnings | 22.13 | |||||
| PS Ratio | 1.62 | |||||
| PB Ratio | 1.44 | |||||
| Price-to-Tangible-Book | 18.07 | |||||
| Price-to-Free-Cash-Flow | 7.87 | |||||
| Price-to-Operating-Cash-Flow | 6.99 | |||||
| EV-to-EBIT | 11.54 | |||||
| EV-to-Forward-EBIT | 9.52 | |||||
| EV-to-EBITDA | 11.54 | |||||
| EV-to-Forward-EBITDA | 5.96 | |||||
| EV-to-Revenue | 1.78 | |||||
| EV-to-Forward-Revenue | 1.71 | |||||
| EV-to-FCF | 8.43 | |||||
| Price-to-Projected-FCF | 0.68 | |||||
| Price-to-Graham-Number | 3.29 | |||||
| Earnings Yield (Greenblatt) % | 8.67 | |||||
| FCF Yield % | 11.21 | |||||
| Forward Rate of Return (Yacktman) % | -16.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
H. Lundbeck AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,704.354 | ||
| EPS (TTM) (€) | 0.326 | ||
| Beta | 0 | ||
| Volatility % | 24.84 | ||
| 14-Day RSI | 65.58 | ||
| 14-Day ATR (€) | 0.066647 | ||
| 20-Day SMA (€) | 4.87845 | ||
| 12-1 Month Momentum % | -7.14 | ||
| 52-Week Range (€) | 4.168 - 5.255 | ||
| Shares Outstanding (Mil) | 992.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
H. Lundbeck AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
H. Lundbeck AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
H. Lundbeck AS Frequently Asked Questions
What is H. Lundbeck AS(WBO:LUNB)'s stock price today?
The current price of WBO:LUNB is €5.06. The 52 week high of WBO:LUNB is €5.26 and 52 week low is €4.17.
When is next earnings date of H. Lundbeck AS(WBO:LUNB)?
The next earnings date of H. Lundbeck AS(WBO:LUNB) is 2024-08-21.
Does H. Lundbeck AS(WBO:LUNB) pay dividends? If so, how much?
The Dividend Yield %  of H. Lundbeck AS(WBO:LUNB) is 1.85% (As of Today), Highest Dividend Payout Ratio of H. Lundbeck AS(WBO:LUNB) was 0.29. The lowest was 0.25. And the median was 0.25. The  Forward Dividend Yield % of H. Lundbeck AS(WBO:LUNB) is 1.85%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers